Novo Nordisk ( Novo Nordisk)

Primary tabs

Novo Nordisk's picture

Management

Contact Address

About Novo Nordisk

Novo Nordisk is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in eight countries, and affiliates or offices in 75 countries. Novo Nordisk is controlled by majority shareholder, Novo A/S, which holds approximately 25% of its shares and a majority 75% voting shares.

Novo Nordisk press release, blog etc

Mon, 12/17/2018 - 11:17 Staten Biotechnology B.V. and Novo Nordisk A/S announce collaboration to develop novel treatment for dyslipidaemia
Fri, 11/23/2018 - 11:49 Oral semaglutide demonstrates favourable cardiovascular safety profile and significant reduction in cardiovascular death and all-cause mortality in people with type 2 diabetes in the PIONEER 6 trial
Thu, 11/22/2018 - 09:05 Oral semaglutide demonstrates greater reductions in both HbA1c and body weight compared to Victoza in Japanese people with type 2 diabetes
Mon, 11/05/2018 - 17:37 Novo Nordisk A/S purchases B shares worth DKK 1,262 million from Novo Holdings A/S under the 2018 share repurchase programme
Fri, 11/02/2018 - 09:21 Embark and Novo Nordisk enter collaboration to discover novel therapeutics for obesity and metabolic disease
Thu, 11/01/2018 - 11:47 Look at our future science
Thu, 11/01/2018 - 06:40 Novo Nordisk's operating profit decreased by 6% in Danish kroner and increased by 2% in local currencies in the first nine months of 2018
Wed, 10/31/2018 - 07:31 Novo Nordisk expands its biopharm business with the acquisition of the US and Canadian rights to Macrilen(TM)
Fri, 10/26/2018 - 05:21 Oral semaglutide demonstrates statistically significant reductions in HbA1c and body weight in people with long duration of type 2 diabetes treated with insulin
Mon, 10/15/2018 - 08:54 Novo Nordisk appoints Ludovic Helfgott executive vice president Biopharm
Fri, 10/12/2018 - 19:10 Fiasp is effective at controlling blood sugar levels in children and adolescents living with type 1 diabetes, when compared to conventional insulin aspart
Tue, 10/02/2018 - 02:05 Ryzodeg offers a simpler solution with once-daily dosing and reduced risk of nocturnal hypoglycaemia vs insulin glargine U100 plus insulin aspart
Tue, 10/02/2018 - 00:58 People with diabetes may achieve improved glycaemic control with Tresiba versus glargine U100, without an increase in hypoglycaemia
Tue, 10/02/2018 - 00:32 Addressing social and cultural drivers of type 2 diabetes is key to its treatment and prevention
Mon, 10/01/2018 - 08:42 Novo Nordisk to establish California manufacturing site for stem cell-based therapies
Mon, 10/01/2018 - 08:30 Novo Nordisk plans first global launch of connected insulin pens and announces key digital health partnerships
Thu, 09/27/2018 - 20:27 International Diabetes Federation (IDF) global survey reveals 2 in 3 people with type 2 diabetes have cardiovascular disease risk factors and/or have experienced a cardiovascular event
Thu, 09/27/2018 - 19:51 New phase 2 data for somapacitan demonstrate its potential as an efficacious once-weekly treatment for childhood growth hormone deficiency
more

InfoBox

HomePagewww.novonordisk.com
Facebookwww.facebook.com/novonordisk
Twittertwitter.com/novonordisk
YouTubewww.youtube.com/user/novonordisk/custom
Instagraminstagram.com/novonordisk
Pinterestwww.pinterest.com/novonordisk
LinkedInwww.linkedin.com/company/novo-nordisk/careers
Wikipediaen.wikipedia.org/wiki/Novo_Nordisk